Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine August 2023, 64 (8) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: Jadvar talks with Carolyn C. Meltzer, MD, Dean of the University of Southern California Keck School of Medicine, about her career in academic radiology and institutional leadership.

Page 1167

PET Braak staging in AD: Macedo and colleagues summarize current efforts to implement Braak staging of Alzheimer disease using PET and assess correspondence between Braak histopathologic descriptions and PET AD biomarkers.

Page 1171

Tracking environmental pollutants: Delaney and colleagues focus on the potential roles of molecular imaging and radiochemistry in characterizing the pharmacokinetic profiles of pollutants at environmentally relevant doses.

Page 1179

SSTR PET in meningioma: Milosevic and colleagues report on institutional experience with somatostatin receptor–targeted [68Ga]-DOTATOC PET/MRI in suspected or diagnosed meningiomas and compare results with those from conventional MRI.

Page 1185

SUVmax and CUP: Zaun and colleagues identify an SUVmax threshold on 18F-FDG PET/CT imaging as a favorable prognostic factor at initial diagnostic workup in patients with cancer of unknown primary.

Page 1191

Metformin and membrane HER: Panikar and colleagues use human epidermal growth factor receptor–targeted PET to study antibody–tumor binding in mice treated with metformin, with implications for both cancer imaging and therapy.

Page 1195

Host–guest chemistry and pretargeted PET: Jallinoja and colleagues describe a cucurbituril host and adamantane guest molecule pairing for antibody-based pretargeted PET in both in vitro and preclinical studies.

Page 1203

68Ga-FAPI-RGD PET: Zhao and colleagues evaluate the clinical cancer imaging characteristics of a 68Ga-labeled heterodimer recognizing both fibroblast-activation protein and integrin αvβ3.

Page 1210

Oncologic FAPI PET/CT: Wass and colleagues provide a systematic review and metaanalysis to assess the diagnostic performance of fibroblast-activation protein inhibitor PET/CT in comparison with [18F]FDG PET/CT.

Page 1218

[18F]FAPI-74 oncologic PET: Watabe and colleagues detail the diagnostic performance of [18F]-labeled fibroblast-activation protein inhibitor-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies.

Page 1225

[68Ga]FAPI-46 PET in pancreatic tumors: Rasinski and colleagues assess the diagnostic accuracy of [68Ga]-fibroblast activation protein inhibitor-46 PET/CT in pancreatic cancer and look at data needed to verify that this technique improves characterization of equivocal lesions.

Page 1232

PSMA PET/CT in unfavorable PCa: Hagens and colleagues determine the diagnostic value of PSMA PET/CT in staging men with newly diagnosed and unfavorable intermediate-risk prostate cancer.

Page 1238

[177Lu]-PSMA RLT in elderly patients: Tauber and colleagues analyze the efficacy and safety of PSMA radioligand therapy in octogenarian patients with metastatic castration-resistant prostate cancer, including data on response and toxicity rates and on predictors of survival.

Page 1244

TheraP PSMA PET eligibility criteria: Karimzadeh and colleagues evaluate outcomes for patients with metastatic castration-resistant prostate cancer treated with PSMA radioligand therapy, focusing on comparisons with TheraP and TheraP-based PET inclusion criteria.

Page 1252

Reader agreement VISION substudy: Kuo and colleagues research interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION trial read criteria, looking at agreement with VISION study results.

Page 1259

177Lu-PSMA RLT in treatment-naïve mCRPC: Satapathy and colleagues explore the impact of prior taxane chemotherapy on response and survival outcomes after [177Lu]Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Page 1266

BMI and overall survival in PSMA RLT: Hartrampf and colleagues investigate fat-related and body composition parameters in patients undergoing PSMA-directed radioligand therapy to assess associated predictive values for overall survival.

Page 1272

Fibroblast activation in TAVR candidates: Diekmann and colleagues use multimodal imaging, including 68Ga-fibroblast activation protein inhibitor-46 PET, to determine the extent and functional correlates of myocardial fibroblast activation in patients with aortic stenosis scheduled for transcatheter aortic valve replacement.

Page 1279

PET/CT in hyperglycemia and infection: Pijl and colleagues describe the effects of blood glucose levels on the performance of 18F-FDG PET/CT for detecting infection foci in patients with bacteremia.

Page 1287

Comparative evaluation of MIRDcalc: Carter and colleagues report on validation of this internal dosimetry software and provide a compendium of radiopharmaceutical dose coefficients obtained with MIRDcalc.

Page 1295

Facial anonymization and total-body PET: Selfridge and colleagues detail development of a workflow that obscures a subject’s face in 3-dimensional volumetric data, with validation in total-body PET/CT imaging.

Page 1304

PET and opioid release after orgasm: Jern and colleagues use [11C]carfentanil PET and PET/MRI to test the hypothesis that sexual arousal peaking in orgasm leads to endogenous opioid release in men.

Page 1310

[18F]FASu and [18F]FSPG: Colovic and colleagues report on a comparison of these amino acid radiopharmaceuticals targeting system Embedded Image, a PET biomarker for oxidative stress, including uptake specificity and ability to image glioma and lung cancer xenografts in vivo.

Page 1314

161Tb-PSMA SPECT/CT: Al-Ibraheem and colleagues present whole-body scintigraphic and SPECT/CT images acquired with this promising agent in a case of metastatic prostate cancer refractory to hormonal therapy and chemotherapy referred for PSMA radioligand treatment.

Page 1322

  • © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (8)
Journal of Nuclear Medicine
Vol. 64, Issue 8
August 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Aug 2023, 64 (8) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Aug 2023, 64 (8) 6A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire